Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticlePractice

Safety of using montelukast during pregnancy

Gideon Koren, Moumita Sarkar and Adrienne Einarson
Canadian Family Physician September 2010; 56 (9) 881-882;
Gideon Koren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Moumita Sarkar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrienne Einarson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

ABSTRACT

QUESTION Montelukast is used more and more by my patients with asthma. Is it safe to use during pregnancy?

ANSWER Cumulative data, including a recent Motherisk study, are very reassuring regarding the use of this drug to treat pregnant patients with asthma.

Asthma adversely affects up to 8% of all pregnancies.1,2 Approximately one-third of pregnant women with asthma remain stable, one-third experience an improvement, and one-third experience a worsening of their condition.3 Untreated asthma leads to increased risk of preterm delivery,4 preeclampsia, vaginal hemorrhage, and pregnancy-induced hypertension.3–7 Montelukast sodium has the advantage of once-daily dosing and oral administration.8 This selective leukotriene receptor antagonist decreases the activation of the cysteinyl leukotriene 1 receptor.9 The American College of Obstetricians and Gynecologists and the American College of Allergy, Asthma and Immunology suggest montelukast as an effective adjuvant therapy in pregnant women for whom resistance to other asthma treatments, or decreased effectiveness of those treatments, has been established before pregnancy.10

In a published study on the safety of leukotriene receptor antagonists in pregnancy, the authors failed to detect any pattern of major malformations in the 72 infants exposed in utero to montelukast.11 In a Swedish registry study examining 129 montelukast-exposed cases, 3 of 7 malformed infants exposed to this drug had cardiac defects.12 Finally, a pregnancy registry maintained by the manufacturer of montelukast contains prospective reports of 185 live births, 7 of which had major congenital anomalies including limb defects.8

We prospectively followed up on 180 cases of montelukast exposure during pregnancy. Analysis of singleton outcomes among montelukast-exposed women resulted in a statistically lower mean (SD) birth weight of 3214.1 (656) g (P = .038) and shorter gestational age at birth (37.8 [3.1] weeks) compared with the nonteratogen-exposed group (P = .045) but not the disease-matched group (P = .891). Moreover, significantly higher rates of fetal distress at delivery (P = .007) were reported by montelukast-exposed women (25.6%) among the 3 groups. Montelukast-exposed infants were statistically different from the nonteratogen control group with respect to birth weight (P = .028) and rate of fetal distress (P = .010), while the disease-matched group differed from the nonteratogen-exposed women with respect to gestational age at birth (P = .046).13

Further subanalysis was conducted on those women who continued to use montelukast until the end of their pregnancies, and it is important to note that the only statistical difference that remained was found in the mean birth weight among the 3 groups (P = .032). Of the 143 infants exposed in utero during organogenesis, there was only 1 case of major malformation reported by a woman exposed to montelukast.13

Exposure to montelukast during pregnancy does not appear to increase the risk of major malformations above the 1% to 3% baseline in the general population. It is important that women are treated effectively for asthma during pregnancy to ensure the best outcome for the mothers.

Notes

MOTHERISK

Motherisk questions are prepared by the Motherisk Team at the Hospital for Sick Children in Toronto, Ont. Dr Koren is Director, Dr Sarkar is a member and Ms Einarson is Assistant Director of the Motherisk Program. Dr Koren is supported by the Research Leadership for Better Pharmacotherapy during Pregnancy and Lactation. He holds the Ivey Chair in Molecular Toxicology in the Department of Medicine at the University of Western Ontario in London.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in women who are pregnant or breastfeeding? We invite you to submit them to the Motherisk Program by fax at 416 813-7562; they will be addressed in future Motherisk Updates.

Published Motherisk Updates are available on the Canadian Family Physician website (www.cfp.ca) and also on the Motherisk website (www.motherisk.org).

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Kwon HL,
    2. Triche EW,
    3. Belanger K,
    4. Bracken MB
    . The epidemiology of asthma during pregnancy: prevalence, diagnosis, and symptoms. Immunol Allergy Clin North Am 2006;26(1):29-62.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Frezzo T,
    2. McMahon CL,
    3. Pergament E
    . Asthma and pregnancy. IL Teratogen Inf Serv 2002;9(2):1-5.
    OpenUrl
  3. 3.↵
    1. Tamási L,
    2. Somoskövi A,
    3. Müller V,
    4. Bártfai Z,
    5. Acs N,
    6. Puhó E,
    7. et al
    . A population-based case-control study on the effect of bronchial asthma during pregnancy for congenital abnormalities of the offspring. J Asthma 2006;43(1):81-6.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Murphy VE,
    2. Clifton VL,
    3. Gibson PG
    . Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes. Thorax 2006;61(2):169-76.
    OpenUrlAbstract/FREE Full Text
  5. 5.
    1. Källén B,
    2. Rydhstroem H,
    3. Aberg A
    . Asthma during pregnancy—a population based study. Eur J Epidemiol 2000;16(2):167-71.
    OpenUrlCrossRefPubMed
  6. 6.
    1. Alexander S,
    2. Dodds L,
    3. Armson BA
    . Perinatal outcomes in women with asthma during pregnancy. Obstet Gynecol 1998;92(3):435-40.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Källén B,
    2. Otterbald Olausson P
    . Use of anti-asthmatic drugs during pregnancy. 2. Infant characteristics excluding congenital malformations. Eur J Clin Pharmacol 2007;63(4):375-81. Epub 2007 Jan 30.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Merck & Co
    . Merck Research Laboratories seventh annual report on exposure during pregnancy from the Merck Pregnancy Registry for SINGULAIR (montelukast sodium) covering the period from U.S. approval (February 20, 1998) through May 22, 2006. West Point, PA: Merck Research Labs; 2008. Available from: www.merckpregnancyregistries.com. Accessed 2010 Jun 25.
  9. 9.↵
    1. Gluck JC,
    2. Gluck PA
    . Asthma controller therapy during pregnancy. Am J Obstet Gynecol 2005;192(2):369-80.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. American College of Obstetricians and Gynecologists, American College of Allergy, Asthma and Immunology
    . The use of newer asthma and allergy medications during pregnancy. Ann Allergy Asthma Immunol 2000;84(5):475-80.
    OpenUrlPubMed
  11. 11.↵
    1. Bakhireva LN,
    2. Jones KL,
    3. Schatz M,
    4. Klonoff-Cohen HS,
    5. Johnson D,
    6. Slymen DJ,
    7. et al
    . Safety of leukotriene receptor antagonists in pregnancy. J Allergy Clin Immunol 2007;119(3):618-25.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Källén B,
    2. Otterbald Olausson P
    . Use of anti-asthmatic drugs during pregnancy. 3. Congenital malformations in the infant. Eur J Clin Pharmacol 2007;63(4):383-8. Epub 2007 Feb 6.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Sarkar M,
    2. Koren G,
    3. Ying A,
    4. Kalra S,
    5. Smorlesi C,
    6. De Santis M,
    7. et al
    . Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes. Eur J Clin Pharmacol 2009 Aug 26. Epub ahead of print.
PreviousNext
Back to top

In this issue

Canadian Family Physician: 56 (9)
Canadian Family Physician
Vol. 56, Issue 9
1 Sep 2010
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Safety of using montelukast during pregnancy
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Safety of using montelukast during pregnancy
Gideon Koren, Moumita Sarkar, Adrienne Einarson
Canadian Family Physician Sep 2010, 56 (9) 881-882;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Safety of using montelukast during pregnancy
Gideon Koren, Moumita Sarkar, Adrienne Einarson
Canadian Family Physician Sep 2010, 56 (9) 881-882;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ABSTRACT
    • Notes
    • Footnotes
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
  • Is 45 the new 50 in colorectal cancer screening?
Show more Practice

Motherisk Update

  • Hepatitis A infection during pregnancy
  • Fluconazole use during breastfeeding
  • Is it safe to breastfeed while taking methylphenidate?
Show more Motherisk Update

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire